輝瑞（Pfizer）2022年第二季度的財報

SecondQuarter2022

EarningsTeleconference

July28,2022

Breakthroughsthatchangepatients'lives?

Introduction

ChristopherStevo

SeniorVicePresident,

ChiefInvestorRelationsOfficer

Forward-LookingStatementsandNon-GAAPFinancialInformation

Ourdiscussionsduringthisconferencecallwillincludeforward-lookingstatementsthataresubjecttosubstantialrisksanduncertaintiesthatcouldcauseactualresults

todiffermateriallyfromthoseexpressedorimpliedbysuchstatements.Weincludeforward-lookingstatementsabout,amongothertopics,ouranticipatedoperatingandfinancialperformance,reorganizations,businessplans,strategyandprospects,ourEnvironmental,SocialandGovernance(ESG)prioritiesandgoals,expectationsforourproductpipeline,in-lineproductsandproductcandidates,includinganticipatedregulatorysubmissions,dataread-outs,studystarts,approvals,clinicaltrialresultsandotherdevelopingdata,revenuecontribution,growth,performance,timingofexclusivityandpotentialbenefits,strategicreviews,capitalallocationobjectives,dividendsandsharerepurchases,plansforandprospectsofouracquisitions,dispositionsandotherbusinessdevelopmentactivities,andourabilitytosuccessfullycapitalizeontheseopportunities,manufacturingandproductsupply,oureffortstorespondtoCOVID-19,includingComirnatyandouroralCOVID-19treatment(Paxlovid),ourexpectationsregardingtheimpactofCOVID-19onourbusiness,operationsandfinancialresults,andourEnvironmental,SocialandGovernancestrategy.Amongotherthings,statementsregardingrevenueandearningspersharegrowth;thedevelopmentorcommercialpotentialofourproductpipeline,in-lineproducts,productcandidatesandadditionalindications,includingexpectedclinicaltrialprotocols,thetimingoftheinitiationandprogressofclinicaltrialsanddataread-outsfromtrials;thetimingforthesubmissionofapplicationsforandreceiptofregulatoryapprovals;expectedprofileandlabeling;andexpectedbreakthrough,bestorfirst-in-classorblockbusterstatusofourmedicinesorvaccinesareforward-lookingandareestimatesthataresubjecttochangeandclinicaltrialandregulatorysuccess.Thesestatementsaresubjecttorisks,uncertaintiesandotherfactorsthatmaycauseactualresultstodiffermateriallyfrompastresults,futureplansandprojectedfutureresults.AdditionalinformationregardingtheseandotherfactorscanbefoundinPfizer’sAnnualReportonForm10-KforthefiscalyearendedDecember31,2021anditssubsequentreportsonForm10-Q,includinginthesectionsthereofcaptioned“RiskFactors”and“Forward-LookingInformationandFactorsThatMayAffectFutureResults”,aswellasinoursubsequentreportsonForm8-K,allofwhicharefiledwiththeU.S.SecuritiesandExchangeCommissionandavailableat

and

.PotentialrisksanduncertaintiesalsoincludetheimpactofCOVID-19onoursalesandoperations,includingimpactsonemployees,manufacturing,supplychain,marketing,researchanddevelopmentandclinicaltrials.Theforward-lookingstatementsinthispresentationspeakonlyasoftheoriginaldateofthispresentationandweundertakenoobligationtoupdateorreviseanyofthesestatements.

Also,thediscussionsduringthisconferencecallwillincludecertainfinancialmeasuresthatwerenotpreparedinaccordancewithU.S.generallyacceptedaccounting

principles(GAAP).Additionalinformationregardingnon-U.S.GAAPfinancialmeasurescanbefoundonslides41-43andinourearningsreleasefurnishedwithPfizer’sCurrentReportonForm8-KdatedJuly28,2022.Anynon-U.S.GAAPfinancialmeasurespresentedarenot,andshouldnotbeviewedas,substitutesforfinancialmeasuresrequiredbyU.S.GAAP,havenostandardizedmeaningprescribedbyU.S.GAAPandmaynotbecomparabletothecalculationofsimilarmeasuresofothercompanies.

Today’sdiscussionsandpresentationareintendedfortheinvestorcommunityonly;theyarenotintendedtopromotetheproductsreferencedhereinorotherwise

influencehealthcareprescribingdecisions.

SecondQuarter2022Earnings3

OpeningRemarks

AlbertBourla

ChairmanandChiefExecutiveOfficer

KeyGrowthDrivers

$8.1B*op

U.S.$4.5B,*

Int'l$3.7B,*op

$552M+16%op

Prevnar

Family(2)

$1.4B+18%op

U.S.$906M,+41%Int'l$523M,-7%op

$1.7B+23%op

U.S.$1.1B,+28%Int'l$681M,+16%op

U.S.$296M,+32%Int'l$256M,+3%op

U.S.$1.1B,-47%Int'l$7.8B,+43%op

$8.8B20%op

(3)

Breakthroughsthatchangepatients’lives.

~845MPatients77%Increase

fromprior-yearquarter

reachedworldwideYTD2022withourmedicinesandvaccines(4)

Q22022KeyHighlights

StrongFinancial

Performance

+53%

OperationalRevenueGrowth

+100%

OperationalAdj.

DilutedEPS(1)Growth

SecondQuarter2022Earnings

*Indicatescalculationnotmeaningful

(1)SeeSlides41-43fordefinitions

(2)PresentedfiguresincludesalesofbothPrevnar/Prevenar13and20

(3)PresentedfiguresincludesalesofbothVyndaqelandVyndamax

(4)Patientcountsareestimatesderivedfrommultipledatasources;~182Mpatientsex-Comirnaty

5

COVID-19:WhereDoWeGoFromHere?

COVID-19

likelytoremainaglobalhealthcareconcern

foryearstocome

Pfizer

well-positionedtocontinue

commercialleadershipin

battleagainst

COVID-19

SecondQuarter2022Earnings

Pfizer'sscience

continuestoaddress

highlymutativevirus

6

Comirnaty:ContinuedLeadershipIntheFightAgainstCOVID-19

CumulativeShareofDoses(1)

(2)

(4)

(3)

Morethan

3.6B

dosesshippedto

180countriesand

territoriestodate(5)

SecondQuarter2022Earnings

(1)MarketsharedataincludesonlythosemarketsinwhichPfizeroperatesandthatreportmarketsharedata

(2)Incl.allmarketsinDevelopedMarkets(3)plusEmergingMarkets(Argentina,Chile,Ecuador,HongKong,Nepal,Peru,SouthAfrica,Uruguay)

(3)IncludestheU.S.,EU/EEA,otherInt'lDevelopedmarkets(Japan,SouthKorea,Switzerland,Ukraine)7

(4)StartingdateofJanuary1,2022forthisdatasetisfromQ12022earningspresentation

(5)FromDecember2020

Omicron-AdaptedCOVID-19VaccineCandidatesforFall2022Boosters

SubmitteddatatoEMA(1)

BA.1BivalentOmicron-modified

FDArequests

BA.4/BA.5BivalentOmicron-modified

Becauseofourrobustmanufacturingcapabilities,weareplanningtodeliverbothvariantvaccinesinthefall,pendingregulatoryapprovals

(1)EuropeanMedicinesAgency

SecondQuarter2022Earnings

8

Paxlovid:ExpandingAccessinU.S.

>41K

siteswithPaxlovidsupplyasofJuly

15

(increaseof>7Ksinceearly-May)

SecondQuarter2022Earnings

OnJuly6,FDArevisedEUA

toauthorizestate-licensed

pharmaciststoprescribe

Paxlovidundercertain

conditions

9

U.S.MarketShare(4)(%)

DatafromQ1earnings

PaxlovidisprescribedmorethananyotherCOVID-19oraltherapy

Paxlovid:NearlyFive-FoldGrowthinU.S.UtilizationSinceQ1(1)

U.S.EstimatedUtilization(NPA)(2)vs.Cases(3)

DatafromQ1earnings

HCPsusingmorePaxlovid,asnumberofreportedCOVID-19casesrises

SecondQuarter2022Earnings

(1)SinceweekendingApril22,2022,thelastweekforwhichdatawaspresentedatQ12022earningsupdate

(2)EstimatedPaxlovidpatientsandestimatedutilizationratescalculatedfromwholesalershippingdataarecomparedtoPaxlovidutilizationfromIQVIA'sNationalPrescriptionAudit(NPA)todetermineestimatedNPAmarketcoverageandsubsequentfactoruprate

(3)Reportedcaseshistoricalareweeklycumulativetotalsderivedfrom

CDCCOVIDDataTracker

forFebruary25,2022toJuly15,2022.

(4)BasedondatafromIQVIAXponent(asofweekendingJuly15,2022),relativetomolnupiravirintheretail,long-termcare,andmailorderchannels,whichtogetherrepresent~80%ofPaxlovidutilization.

10

Paxlovid:ExpandingAccessinInternationalDevelopedMarkets

RecentwaveofBA.4/BA.5resultingin

increasedhospitalizations,ICUadmissionsanddeaths(1)

Averagedailydeathsincreasedfrom6/24-7/24

Europe(2):~2x(0.61.15per1Mpeople)

Japan:~3x(0.120.34per1Mpeople)

inusageacrossinternationaldevelopedmarkets

~116%increase(3)

SecondQuarter2022Earnings

(1)BasedondataoverthemonthfromJune24,2022toJuly24,2022from

OurWorldinData

(ICUadmissionsanddeaths)and

ECDCdata

(hospitalizations)

(2)IncludesEUandnon-EUcountries

(3)BasedoninternalestimatescomparingJune24,2022toJuly15,2022

11

Successful

U.S.Launch

Q2U.S.AdultRevenue(1)

337%op

vsprioryear

quarter,to

$431M

97%

Market

Share

Strong

Uptake

Simplicityof1-shot

Prevnar20Adult:Market-LeadingU.S.Performance

RoutineRecommendation

19-64Years

withunderlyingmedicalcondition

(1)Prevnar13andPrevnar20Adultrevenue-Prevnar20representedmorethan3/4oftotalAdultrevenue

12

SecondQuarter2022Earnings

Firstquarterly

uptickinU.S.

revenuessince

Q42020

Ibrance:EncouragingU.S.Trends

Q2U.S.Revenues

Up1%

vsprioryearquarter

despitecontinuedincreaseinproportion

ofpatientsaccessingIbrancethroughour

PatientAssistanceProgram

Q2U.S.TotalVolumeDemand(1)

Up3%

vsprioryearquarter

(1)Totalvolumedispensed

13

SecondQuarter2022Earnings

Net-ZeroStandard(2)

?GoaltoachieveNet-ZeroStandardacrossourvaluechainby2040,tenyearsaheadofanewvoluntaryexternalstandard

ESG:TurningCommitmentintoAction

ClimateChange

EquitableAccessandAffordability

AccordforaHealthierWorld(1)

?AllcurrentandfuturePfizerpatentedmedicinesandvaccinesavailableinU.S.andEUtobeofferedonanot-for-profitbasisto1.2Bpeoplein45lower-incomecountries

?FirstproducthasarrivedinRwanda

(1)See

May25,2022pressrelease

(2)See

June30,2022Pfizerstatement

SecondQuarter2022Earnings

BusinessEthics

SupportforUkraine(3)

?DonatingequivalentofallprofitsfromoursalesinRussiatocausesthatprovidedirecthumanitariansupporttopeopleofUkraine

?Firstdownpaymentof$5Mto8globalandlocalNGOs

?ContinuingtoservepatientswhilehelpingthepeopleofUkraine

(3)See

June22,2022Pfizerstatement

14

MSCIESGRatingUpgrade

Toxic

Product

Safety&Quality

CorporateBehaviour

Rating&

Emissions

Accessto

HumanCapital

Trend

&Waste

HealthCare

Corporate

Governance

PfizerInc.

A

BBB

BBB

July

2022

June

2021

TopQuartile

UpgradeUpgradebytwoormorenotchesDowngradeDowngradebytwoormorenotches

QuartileKey:BottomQuartile

RatingTrendKey:Maintain

SecondQuarter2022Earnings15

ScientificUpdates

MikaelDolsten

ChiefScientificOfficerandPresident,

WorldwideResearch,Developmentand

Medical

CharlotteAllerton

ChiefScientificOfficer,Anti-InfectivesHeadofMedicineDesign

LeadingtheWaytoBreakthroughs

DeepexpertiseandsuccessfultrackrecordinCOVID-19andinfectiousdisease

AnnaliesaAnderson,Ph.D.,FAAM

SeniorVicePresidentandHead,

VaccineResearch&Development

SecondQuarter2022Earnings17

ThePandemicContinuestoEvolve

Newvariantsemerginginshortertimeintervals

GlobalCirculatingStrainsTrend

COVID-19GlobalCases/Deaths

~565M

GlobalCases

~6.4M

GlobalDeaths

GISAIDdataasofJuly22,2022

AsofJuly19,2022:JohnHopkinsUniversityCovid-19

site:

/

18

SecondQuarter2022Earnings

AdvancingOmicronVariant-modifiedVaccineCandidates

Evaluatedsafety&immunogenicityofmono-andbivalentOmicron(BA.1)–modifiedvaccinecandidatesin~1,920participants>55years

BNT162b2

BNT162b2

MonovalentBNT162b2

Omi(BA.1)

BivalentBNT162b2+BNT162b2Omi(BA.1)

or

or

Dose4administeredamedianof6.3months(4.7,12.9)fromDose3

?MonovalentBNT162b2Omi(BA.1),bivalentBNT162b2+BNT162b2Omi(BA.1)alsobeingevaluatedinparticipants18-55yearsofage

?30μgbivalentcandidateselectedfollowingguidancefromregulators

SimplifiedstudyschemefromSubstudyE:evaluatingsafety&immunogenicityofmono-andbivalentOmicron(BA.1)–modifiedvaccinecandidatesin~1,920participants>55yearsat30or60μg,n=320eachPresentedatJune28,2022VaccinesandRelatedBiologicalProductsAdvisoryCommittee.

SecondQuarter2022Earnings19

LOD

AdvancingOmicronVariant-ModifiedVaccineCandidates

Insub-studyevaluatingBA.1-modifiedvaccine

candidatescomparedtowildtypevaccine,

resultsforOmicronBA.1demonstrate:

?GMRconsistentwithsimplesuperiority

criterion

?Seroresponserateexceedsnoninferiority

criterion

with4thdosebooster

?Similarlocalreactionandsystemicevent

?Neutralizationactivitysubstantiallyincreased

profiletowildtypevaccine

BA.4/BA.5responsetoBA.1-modifiedvaccinecandidate

ParticipantsWITHOUTEvidenceofInfectionupto1MonthAfterFirstStudyVaccination

OmicronresponsestoBA.1-

modifiedvaccinecandidates

werehigheroverall

comparedtotheoriginal

vaccine,thoughBA.4/5was

lowerthanBA.1

ResultsfromSubstudyE:evaluatingsafety&immunogenicityofmono-andbivalentOmicron(BA.1)–modifiedvaccinecandidatesin~1,920participants>55years;

FFRNT,fluorescentfocireductionneutralizationtest;LOD,LimitofDetection

PresentedatJune28,2022VaccinesandRelatedBiologicalProductsAdvisoryCommittee

20

SecondQuarter2022Earnings

OmicronBA.4/5MonovalentandBivalentBoostersinMice

SubstantialincreaseinOmicronneutralizationresponsestoallOmicronvariants

BNT162b2OmicronBA.1MonovalentOmicronBA.4/5MonovalentOmicronBA.4/5Bivalent

n=8.Micepreimmunizedwith2dosesofBNT162b2;boostersgivenatday104

pVN=Pseudovirusneutralizationassay;LOD=LimitofDetection;GMT=Geometricmeantiter

PresentedatJune28,2022VaccinesandRelatedBiologicalProductsAdvisoryCommittee

21

SecondQuarter2022Earnings

BivalentBoosterStrategytoAdapttoPaceofVirus

Potentialtoenableamorerapidresponsetochangingvariantlandscape

Variant

Vaccine

Regulatory

Update

Pathway

USACirculatingOmicronStrainsTrend

?OmicronBA.1

?OmicronBA.2

?OmicronBA2.12.1?OmicronBA.4

?OmicronBA.5

?Overallresponsessimilarbetweenhumanclinicalandmousedata

?ExtensiveclinicalexperiencewithvariantmodifiedvaccineswithsamemRNAplatformandmanufacturingmayenablepreclinicalimmunogenicitydataandbivalentCMCpackagetobesufficientforfutureEUAs1

GISAIDdataasofJuly22,2022

(1)Subjecttoregulatoryagreement.

SecondQuarter2022Earnings22

wildtype

SecondQuarter2022Earnings

23

StrategiesAimingtoProvideDurableDiseaseProtectionAgainst

EmergingVariants

Next-generationSARS-CoV-2SpikeAntigen

?Phase1/2studyinitiatedwithbivalentvaccinecandidate(WTandOmicronBA.2)

?Next-generationspikeproteinengineeringaimsto:

?Increaseprefusionstability

?Exposemoreneutralization-sensitiveepitopes

FutureProof-of-ConceptStudyPlannedforClinic2H2022

?Pan-SARS-CoV-2vaccinecandidate

WT=

Hospitalized

HighRisk

ContinuedExpansionofPAXLOVIDClinicalStudies

Immunocompromised

Study

EPIC-HR1

EPIC-IC

EPIC-Hos4

TrialSize

2,246

150

279

Milestone

PDUFADateExpectedQ120232,3

PlannedStudyStart2H20222

PlannedStudyStart2H20222

LongCOVID

Pregnancy

Retreatment

Study

Multiplecollaborativestudiesbeingconsidered

WorkingwithFDAtofinalizeprotocol

NCT05386472

TrialSize

45

Milestone

Ongoing

EPIC=EvaluationofProteaseInhibitionforCOVID-19;HR=HighRisk;IC=Immunocompromised;Hos=Hospitalized

(1)StudyresultspublishedinNEJM2022;386:1397-1408DOI:10.1056.

(2)Anticipatedtiming,underreviewandsubjecttochange.

(3)NDAsubmissionsupportedbydatafromEPIC-HR,EPIC-SR(SR=StandardRisk),andEPIC-PEP(PEP=Post-ExposureProphylaxis)

(4)ICandnon-IChigh-riskhospitalizedpatients

24

SecondQuarter2022Earnings

CurrentFluVaccinesareSuboptimalinAddressingUnmetNeed

mRNAplatformshortenstimelinespotentiallyenablingquickerresponsetofluevolution

3–5M

Severecases/yrglobally1

5-20%USpopulationbecomesinfected

with≥200Khospitalizationsand

upto79Kdeaths/yr2

Elderlyaccountfor

70–85%

ofdeaths3

Upto

$25B

ineconomiclossinU.S.4

Inefficientfluvaccinecycleresultsinsuboptimaleffectiveness

PotentialAdvantagesofmRNAvaccinesforFlu:

?Improvedstrainmatch

?Morerapid,reliablemanufacturingtofacilitateseasonalstrainchanges

?Broaderimmuneresponses(bothantibodies&Tcells)

(1)WorldHealthOrganization:

/mediacentre/factsheets/fs211/en/

;

(2)CentersforDiseaseControlandPrevention:

/flu/about/qa/disease.htm

;

(3)CentersforDiseaseControlandPrevention:

/flu/highrisk/65over.htm

(4)Putrietal,Vaccine.2018Jun22;36(27):3960-3966.doi:10.1016/j.vaccine.2018.05.057

25

SecondQuarter2022Earnings

N2-foldqRNAGMFRsforB/VictoriaandH3N2>QIVatDay7

**

QIVn=44

qRNAn=35

Strain-SpecificCD8+TcellResponses

QuadrivalentmodRNAFluVaccineCandidate:OngoingPhase2Study

FirstevidenceofsubstantialinductionofbothCD4+andCD8+responses

Phase2ExpansionStudyinSubjects65+YearsofAge(n=118)

N2-foldqRNAGMFRsforall4strains>QIVatDay7

Strain-SpecificCD4+TcellResponses

*

*

*

*

QIVn=44qRNAn=35

Phase3studyplanningbasedonencouragingTcellresponsesandseroconversion

modRNA=modifiedRNA;qRNA=quadrivalentmodRNA;QIV=quadrivalentinfluenzavaccine(FluzoneHD);HA1=hemagglutininA;H1N1=InfluenzaASubtype;H3N2=InfluenzaASubtype;BYAM=YamagataB

Subtype;BVIC=VictoriaBSubtype;GMFR=GeometricMeanFoldRise

(*)GMFRaxis:HighestQIVstrain-specificIFNy+CD4orCD8TcellresponsesatDay7;%ResponderRateaxis:HighestresponderrateforQIV

26

SecondQuarter2022Earnings

MeanDailyGlucose

Reduction(mg/dL)

0

PF-07081532:PotentialBest-In-ClassOnce-DailyOralGLP-1Profile

UpcomingEASDPhase1datashowrapid,robustreductioninglucoseandbodyweight1

99mg/dLReductioninMeanDailyGlucoseafter6weeks1

Placebo

PF-07081532

-20

-40

-29

-60

-80

-100

-99

-120

5kgReductioninBodyWeightafter6weeks1

BodyweightReduction(kg)

0

-1

-2

-3

-4

-5

-6

Placebo

PF-07081532

-2

-5

?Similarchangesinbodyweightobservedinparticipantswithnon-diabeticobesity

?SafetyandtolerabilityprofileconsistentwithGLP-1RAclass,furthertitrationoptimizationinplannedPhase2Study

?Threepresentations2acrossoralGLP-1RAfranchiseatEASDAnnualMeeting,September2022

EASD=EuropeanAssociationfortheStudyofDiabetes;T2DM=Type2DiabetesMellitus;GLP-1=Glucagon-likePeptide-1;RA=ReceptorAgonist

ResultsfromCidentifier:NCT04305587,Randomized,double-blind,placebo-controlled,multipleascendingdosePhase1StudyinadultswithT2DMandnon-diabeticobesity

SecondQuarter2022Earnings

(1)Abstract#114,58thAnnualMeeting-Once-DailyOralSmallMoleculeGLP-1RAgonistPF-07081532RobustlyReducesGlucoseandBodyWeightwithin4-6WeeksinAdultswithT2DMandNon-DiabeticAdultswithObesity,Modelledmeanspresented,Meanbaselinedailyglucose212mg/dL,MeanbaselinebodyweightinT2DMparticipants90kg

(2)Abstracts#114,588,589

27

Anti-IFN-β:PotentialtoAddressKeyDriverofAutoimmunity

?IFN-βisoneof~20TypeIinterferonswhichareimportantfornormalimmunefunction

?AdministrationofIFN-βcanleadtoautoimmunityinpeople

?PatientswithdermatomyositisshowelevatedTypeIIFNgenesignatureinblood,skinandmuscle,correlateswithdiseaseactivityinskin

?BlockingIFN-βhaspotentialforbroaderutilizationinotherinflammatoryautoimmunediseasessuchaslupus(~200,000U.S.patients1)

Anti-IFN-βinDermatomyositis(DM)

?DMislife-threateningandchronicallydebilitating

?Manifestationsincludeskinlesionsandprogressivelydebilitatingmuscleweakness,cardiacimpairment,lungandjointmanifestations,increasedriskofmalignancy

?Approximately50,000dermatomyositis(DM)and50,000–55,000polymyositis(PM)U.S.patients

?OpportunitytobefirstapprovedtargetedtherapyforDMandPM2

(1)

/chronicdisease/resources/publications/factsheets/lupus.htm

(2)Subjecttoclinicaltrialsuccess/regulatoryreview

28

SecondQuarter2022Earnings

AmendedStage2

Stage3

Efficacy

SkinPredominantDisease

?Bothdoses(600mgand150mg)metprimaryefficacyendpointasassessedbyCutaneousDermatomyositisDiseaseAreaandSeverityIndex(CDASI-A)

MusclePredominantDisease

?Numericallybetterefficacyscoresacrossallkeymuscleendpoints

Safety

?Generallywelltoleratedwithfavorablesafetyprofileinallstagesofthestudy,nosafetysignalsidentified

?NocasesofHerpesZosterorHerpesSimplex

Anti-IFN-β:UpdatedPhase2DermatomyositisPositiveData

Phase2,PlaceboControlledStudy

Skin

Muscle

Stage3

Stage1

Stage2

AmendedStage2

Stage1

Stage2

Skin

Skin

Skin

Predominant

Predominant

Predominant

Disease

Disease

Disease

Dose

Fixed

Ranging

Sequence

n=9

n=32

n=16

Muscle

Predominant

Disease

n=18

ResultsstrengthengrowingI&Iportfoliowithdiversemechanismstohelpaddressmultipledriversofdiseaseandunmetneed

SecondQuarter2022Earnings29

Efficacy:

?ConfirmedORRwas64%among55patients

?35%ofpatients(19/55)achievedsCRorCR

?54%(7/13)ofpatientswhoreceivedpriorBCMA-directedtherapy(ADCorCAR-T)achievedaresponse

?Forresponders(n=35),theprobabilityofbeingeventfreeat9monthswas77%(95%CI,58-88%)

Safety:

?Manageablesafetyprofile

?Withpre-medicationand1-steppriming,noGrade

3orhigherCRS,incidencewas66.7%dividedequallybetweenGrade1and2

Follow-upPhase1MagnetisMM-1TrialofelranatamabforMM

ASCO1resultsshowconfirmedORRof64%inpatientswithRRMM

DurationofTreatmentandBestOverallResponseforAllPatients

MM=MultipleMyelomia;RRMM=Relapsed/refractorymultiplemyeloma;ASCO=AmericanSocietyofClinicalOncology;ADC=

antibodydrugconjugate;BCMA=B-cellmaturationantigen;CAR-T=chimericantigenreceptorT-celltherapy;CR=completeresponse;MR=minimalresponse;NE=notevaluable;ORR=overallresponserate;PD=progressivedisease;PR=partialresponse;REL=relapse;sCR=stringentcompleteresponse;SD=stabledisease;VGPR=verygoodpartialresponse;CRS=cytokinereleasesyndrome

(1)Abstract#8014,ASCO2022AnnualMeeting:Elranatamab,aBCMA-TargetedT-CellRedirectingImmunotherapy,forPatientswithRelapsedorRefractoryMultipleMyeloma:UpdatedResultsfromMagnetisMM-1

30

SecondQuarter2022Earnings

Follow-upPhase1MagnetisMM-1TrialofelranatamabforMM

ASCO1resultsshowdurableMRDnegativity

DurationofTreatmentandMolecularResponseforCR/sCRPatients

MM=multiplemyeloma;MRD=Minimalresidualdisease;RRMM=Relapsed/refractorymultiplemyeloma;ASCO=AmericanSocietyofClinicalOncology;CR=completeresponse;sCR=stringentcompleteresponse

(1)Abstract#8014,ASCO2022AnnualMeeting:Elranatamab,aBCMA-TargetedT-CellRedirectingImmunotherapy,forPatientswithRelapsedorRefractoryMultipleMyeloma:UpdatedResultsfromMagnetisMM-1

(2)Triple-ClassRefractoryMultipleMyeloma:ClinicalTIdentifier:NCT04649359

(3)Double-ClassExposedMultipleMyeloma;ClinicalTIdentifier:NCT05020236

(4)Newlydiagnosedpost-transplantMultipleMyelomaClinicalTIdentifier:NCT05317416

MRDNegativity:

?100%(13/13)ofevaluableCR/sCRpatients(includingunconfirmed)achievedMRDnegativityatasensitivityof1x10-5

?Molecularresponsesweredurablewith62%(8/13)documentedMRDnegativeat>6months,including2patientsMRDnegativebeyond18months

MagnetisMM-1results,andemergingdata

fromMagnetisMM-32,supportfurther

developmentacrossabroaderprogram

withpotentialregistra